Investment Thesis
Theravance demonstrates exceptional cash generation ($238.5M OCF) and revenue growth (+66.9% YoY) with a fortress balance sheet ($167.8M cash, zero debt). However, negative operating income (-3.4% margin) indicates core operations are not yet profitable, with net income appearing driven by non-operating gains that may not be sustainable.
Strengths
- Exceptional cash generation: $238.5M operating cash flow on $107.5M revenue signals strong underlying business fundamentals
- Fortress balance sheet: $167.8M cash, zero debt, 10.93x current ratio provides significant financial flexibility
- Strong revenue growth: 66.9% YoY growth indicates successful commercialization or new partnerships
- Excellent returns: 35.7% ROE and 21.8% ROA demonstrate efficient capital deployment
Risks
- Operating income is negative (-3.4% margin), indicating core business operations are not yet profitable
- Net income driven by non-operating gains, suggesting reliance on one-time events rather than operational earnings sustainability
- Pharmaceutical sector inherent risks: regulatory, clinical trial failures, patent expirations, and product pipeline execution
- Disconnect between operating income and net income reduces visibility into true operational performance
Key Metrics to Watch
- Operating margin trend and path to profitability
- Source and sustainability of non-operating gains
- Operating cash flow trajectory relative to revenue growth
- R&D efficiency and drug pipeline advancement status
- Cash burn rate and runway given current cash position
Financial Metrics
Revenue
107.5M
Net Income
105.9M
EPS (Diluted)
$2.06
Free Cash Flow
238.5M
Total Assets
485.6M
Cash
167.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-3.4%
Net Margin
98.5%
ROE
35.7%
ROA
21.8%
FCF Margin
221.9%
Balance Sheet & Liquidity
Current Ratio
10.93x
Quick Ratio
10.93x
Debt/Equity
0.00x
Debt/Assets
0.0%
Interest Coverage
-5.73x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-17T04:21:26.699000 |
Data as of: 2025-12-31 |
Powered by Claude AI